Intellia Therapeutics, Inc. $NTLA Shares Acquired by PDT Partners LLC

Key Points

• PDT Partners LLC has increased its stake in Intellia Therapeutics by 40.5%, now owning 460,246 shares worth approximately $3.27 million after purchasing an additional 132,638 shares.
• Intellia Therapeutics recently reported revenue of $14.25 million for the quarter, exceeding analyst estimates and showing a year-over-year growth of 104.3%.
• The company's stock currently has a consensus rating of "Moderate Buy" among analysts, with a price target averaging $29.05.

PDT Partners LLC boosted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 40.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 460,246 shares of the company's stock after buying an additional 132,638 shares during the quarter. PDT Partners LLC owned 0.44% of Intellia Therapeutics worth $3,272,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. grew its position in Intellia Therapeutics by 51.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 19,726 shares of the company's stock worth $140,000 after buying an additional 6,722 shares during the period. D.A. Davidson & CO. grew its position in shares of Intellia Therapeutics by 76.2% in the first quarter. D.A. Davidson & CO. now owns 26,020 shares of the company's stock valued at $185,000 after purchasing an additional 11,250 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Intellia Therapeutics by 4.1% in the fourth quarter. California State Teachers Retirement System now owns 90,638 shares of the company's stock valued at $1,057,000 after purchasing an additional 3,596 shares during the last quarter. XTX Topco Ltd grew its position in shares of Intellia Therapeutics by 84.2% in the first quarter. XTX Topco Ltd now owns 80,897 shares of the company's stock valued at $575,000 after purchasing an additional 36,989 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Intellia Therapeutics by 5.5% in the first quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company's stock valued at $76,447,000 after purchasing an additional 561,978 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NTLA has been the topic of several research reports. Wall Street Zen upgraded shares of Intellia Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. HC Wainwright lowered their price target on shares of Intellia Therapeutics from $30.00 to $25.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Wells Fargo & Company reiterated an "overweight" rating and issued a $45.00 price target (down from $50.00) on shares of Intellia Therapeutics in a research report on Friday, August 8th. Chardan Capital lowered their price target on shares of Intellia Therapeutics from $68.00 to $60.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Finally, Royal Bank Of Canada decreased their target price on shares of Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Twelve research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Intellia Therapeutics has an average rating of "Moderate Buy" and an average target price of $29.05.

Insiders Place Their Bets

In other news, Director William J. Chase purchased 100,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was acquired at an average cost of $10.03 per share, with a total value of $1,003,000.00. Following the acquisition, the director owned 134,693 shares in the company, valued at approximately $1,350,970.79. This trade represents a 288.24% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Edward J. Dulac III sold 7,462 shares of the firm's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total transaction of $104,617.24. Following the sale, the executive vice president directly owned 106,062 shares of the company's stock, valued at approximately $1,486,989.24. The trade was a 6.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,534 shares of company stock valued at $153,837. Company insiders own 3.10% of the company's stock.

Intellia Therapeutics Stock Up 3.8%

Shares of NTLA stock traded up $0.44 during mid-day trading on Friday, reaching $12.06. The company's stock had a trading volume of 5,156,129 shares, compared to its average volume of 4,096,285. The company's 50 day simple moving average is $11.49 and its 200-day simple moving average is $9.58. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $23.76. The firm has a market capitalization of $1.29 billion, a PE ratio of -2.57 and a beta of 2.28.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, beating analysts' consensus estimates of ($1.03) by $0.04. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. The business had revenue of $14.25 million for the quarter, compared to the consensus estimate of $12.26 million. During the same quarter last year, the firm posted ($1.52) EPS. The business's revenue for the quarter was up 104.3% compared to the same quarter last year. As a group, research analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.